Ocular Therapeutix's stock plummeted 6.86% during intraday trading on Tuesday, following the release of its first-quarter 2026 financial results.
The biopharmaceutical company reported a quarterly loss of $0.40 per share, which missed the analyst consensus estimate of a $0.33 loss. Revenue for the quarter was $10.785 million, falling short of the $12.599 million estimate. The net loss widened to $88.6 million from $64.1 million a year earlier, driven by a significant increase in research and development expenses to $66.2 million from $42.9 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments